Vitamin D in Prevention of Preeclampsia

Authors
Akanksha Tiwari¹, Dr Jyoti Batra², Dr Srikant Sharma³, Dr Alpana Aggrawal⁴
¹MBBS-IIIrd year, Santosh Medical College and Hospital, Ghaziabad
²Dean (Research) and Professor, Department of Biochemistry, Santosh Medical College and Hospital, Ghaziabad
³Senior Consultant, Department of Internal Medicine, Moolchand Khairati Ram Hospital and Ayurvedic Research Institute, New Delhi
⁴Professor and HOD, Department of Obstetrics and Gynaecology; Santosh Medical College and Hospital, Ghaziabad
*Corresponding Author
Dr Jyoti Batra
Dean (Research) and Professor, Department of Biochemistry, Santosh Medical College and Hospital, Ghaziabad, India

Abstract
The present study aimed to analyse the relation between vitamin D and preeclampsia. 120 pregnant females with a single ton pregnancy (healthy/preeclamptic) were selected and their body mass index was determined. They were further divided into four groups; normotensive patients with body mass index<25 kg/m² (Group-I, N=30 ‘CONTROL’), normotensive patients with body mass index>25 kg/m² (Group-II, N=30), preeclamptic patients with body mass index<25 kg/m² (Group-III, N=30), and preeclamptic patients with body mass index>25 kg/m² (Group-IV, N=30). Their serum 25 OH D levels were analysed. Through the analysis, preeclamptic patients showed significantly reduced serum levels of vitamin D and a positive association between low vitamin D levels and preeclampsia was observed.

Keywords: Hypertension; Preeclampsia; 25 OHD; Vitamin D; Body Mass Index.

Introduction
Preeclampsia (PE) is a pregnancy-specific hypertensive disorder which usually occurs after 20 weeks of gestation. Classically, PE is defined by the occurrence of new-onset hypertension and new-onset proteinuria; Hypertension, defined as either a systolic blood pressure ≥ 140 mm Hg, a diastolic blood pressure ≥ 90 mm Hg, or both with at least two determinations for diagnosis of blood pressure at least 4 hours apart (although in severe hypertension, the time interval can be reduced even under minutes). Proteinuria is diagnosed with excretion of ≥ 300mg protein in the urine sample of 24-hour excretion or the ratio of measured protein to creatinine in a single voided urine is ≥ 3.0 mg/dl with, qualitative dipstick readings of 1+. However, some women experience an absence of proteinuria, therefore there has been a revision on the diagnostic criterions for PE, as now being
defined with the involvement of multisystem etiologies. For a legitimate diagnosis certain multi systemic signs are taken under review including, thrombocytopenia (platelet count less than 100,000/microliter), impaired liver function (elevated blood levels of liver transaminases to twice the normal concentration), the new development of renal insufficiency (elevated serum creatinine greater than 1.1 mg/dl or a doubling of serum creatinine in the absence of other renal disease), pulmonary edema, or new-onset cerebral or visual disturbances are taken into consideration for the diagnosis of PE\(^1\).

The incidence of PE ranges between 8-10% in India while 2-10% of pregnancies worldwide\(^2\). The complications of PE include Eclampsia, Disseminated Intravascular Coagulation (DIC) and the Haemolytic anaemia-Elevated Liver enzymes-Low Platelets (HELLP)- syndrome. Risks to the foetus include Intrauterine Growth Restriction (IUGR) and foetal death. Studies have shown that insufficient intake of vitamin D, calcium, magnesium, selenium, vitamin A and vitamin C, has a role in immunomodulation and impaired placental development\(^3\)(\(^4\)). In a study conducted by Benachi A. et al, it was found that women with vitamin D sufficiency during the 1st and 3rd trimesters had a significantly lower risk of PE\(^5\) and that Vitamin-supplementation can reduce the onset of PE\(^6\).

The objectives of the present study were:

1. To measure the concentration of 25-hydroxyvitamin D (25 OH D), from the withdrawn blood sample.
2. To record anthropometric data of the PE patients.
3. To confirm an association between PE and vitamin D levels.

Methods

A total of 120 antenatal patients were included in the study. Their blood pressure was measured on the left arm using mercury column sphygmomanometer; the individual was made comfortable and seated back in rest at least for five minutes in their chair before measurement. Covering 2/3 rd of the arm, 1 inch above the cubital line, 3 subsequent readings were taken and their average was calculated. Their anthropometric data were also recorded and thereafter, were divided into four groups.

1. Group I (control): 30 normotensive and non-overweight (BMI<25kg/m\(^2\))/non-obese subjects.
2. Group II: 30 normotensive and overweight/obese subjects (BMI>30kg/m\(^2\)).
3. Group III: 30 preeclamptic and non-overweight/non-obese subjects
4. Group IV: 30 preeclamptic and overweight/obese subjects.

Patients were screened for vitamin D deficiency using the Chemiluminescence immunoassay method (CLIA) and the levels were expressed in ‘ng/ml’ (deficiency <30 ng/ml).

Statistical analysis was performed by the Statistical Package for the Social Sciences (SPSS) program for Windows, version 17.0. Continuous variables were presented as Mean ± SD. For all statistical tests, a p-value less than 0.05 was taken to indicate a significant difference.

Results

In the present study, we found a positive association between serum deficiency of vitamin D and PE. It was observed that Group-I & Group-II had normal serum levels of vitamin D. While the patients under the Group-III and Group-IV showed a serum deficiency of vitamin D (Table 1) (Figure 1).
Table 1: Comparison of Vitamin D levels in different groups.

| Characteristic variables | Group-I; N=20 CONTROL | Group-II; N=20 | Group-III; N=20 | Group-IV; N=20 |
|--------------------------|-----------------------|----------------|----------------|----------------|
| Vitamin D (ng/ml)        | Mean: 32.747          | 34.408         | 23.991         | 22.713         |
|                          | SD: 8.721             | 7.802          | 7.328          | 5.970          |
|                          | Mean difference:      | tilted         | 1.661          | 8.756          | 10.034         |
|                          | Std. error:           | 2.136          | 2.079          | 1.930          |
|                          | p-Value:              | 0.969          | 0.001          | 0.000          |

Discussion

Preeclampsia is a hypertensive disorder of pregnancy, comprising of its own serious complications, including eclampsia. This study aimed to assess whether vitamin D could be associated with the pathological factors contributing towards the hypertensive disorder as vitamin D deficiency have often been linked to certain maternal and foetal morbidities and co-morbidities by different studies conducted in the past decade, also being recognized as a matter of public health concern lately.

In general, PE has been hypothesised as a two-stage disorder. In stage-1, there occurs an impaired remodelling of the spiral artery due to the trophoblastic invasion on walls of the uterus, producing placental ischemia and an increase in oxidative stress leading to decreased uteroplacental perfusion followed by stage-2 in which, there occurs severe endothelial damage, further aggravating the oxidative stress. In a study conducted by Robert JM et al. reveals the presence of numerous infarcts in placental arterioles with significant sclerotic narrowing of preeclamptic patients\(^7\).

Vitamin D is a known antioxidant and is debated for its role in downregulation of some of the known etiological factors of the PE. Vitamin D is proved to induce Vascular Endothelial Growth Factor (VEGF) release and also increase the release and activity of Pro-Matrix Metalloproteinase (pro-MMP-2)\(^8\) thus promoting angiogenesis, and which is otherwise unregulated in the placenta of preeclamptic pregnancies as explained above. Vitamin D is released by endothelial cells\(^9\) and causes vascular smooth muscle cell proliferation\(^10\). Vitamin D supplementations have been shown to reverse endothelial dysfunction in PE (11) possibly via increased VEGF release\(^12\).

In PE, soluble fms–like tyrosine kinase 1 (sFlt-1) seems to be a key mediator in the development of PE. Gilbert JS and Makris A et al. in their studies have associated uteroplacental hypoperfusion with elevated levels of sFlt-1 leading to PE.\(^13\)(14). In a study conducted by Maynard et al. it was observed that levels of sFlt-1 were increased in the
circulation of preeclamptic women. sFlt-1 is an analogue of VEGF receptor fms–like tyrosine kinase 1. When the levels of sFlt-1 are abnormally increased, it competitively binds to VEGF and placental growth factor (PIGF), thus antagonizing their binding to cell surface receptor fms–like tyrosine kinase 1 (VEGF receptor 1) creating an angiogenic imbalance leading to increased chances of endothelial damages\textsuperscript{15}.

Vitamin D supplementation reduces endothelial dysfunction by decreasing apoptosis and increasing Nitric Oxide (NO) production, as well as reduced the expression of sFlt-1 in Reduced Uterine Perfusion Pressure (RUPP) modelled rats. Vitamin D supplementation also decreased the activity of caspase-3 in RUPP rats thereby, alleviating PE characteristic symptoms\textsuperscript{16}.

Another important etiological factor of PE includes NO, which is a potent vasodilator, the levels of which are found deranged in PE. NO deficiency causes impaired spiral artery remodelling and PE-characteristic uteroplacental changes in pregnant mice\textsuperscript{17}. NO deficiency has also been shown to correlate with derangements seen in PE, including hypertension and proteinuria\textsuperscript{18}.

Vitamin D is a known immunomodulator, as it decreases the anti-angiogenic factors, including reducing the production of γ-Interferon (IF-γ) and Interleukin-2 (IL-2)\textsuperscript{19}, Tumor Necrosis Factor-α (TNF-α), and Interleukin-6 (IL-6) secretions\textsuperscript{20}. In a study conducted by Martinez-Miguel P et. al. demonstrated that active vitamin D increases NO production in endothelial cells, as well as increases the activity of Endothelin-Converting Enzyme-1 (ECE-1) and Endothelial-Nitric Oxide Synthase (eNOS)\textsuperscript{21}.

Although, there are other proximal pathways of sFlt-1 induction, including downregulation of levels of Heme Oxygenase (HO). The HO enzyme degrades heme into carbon monoxide (CO) which is a vasodilator. In states of hypoxia and ischemia, levels of HO increases, thus leading to increased expression of CO resulting in decreased perfusion pressure in placenta\textsuperscript{22-24}. In a study by McCaig D. et al. shows defective trophoblastic invasion which is characteristic of PE due to decreased HO levels\textsuperscript{25}. Various studies have been conducted which proves that in patients with PE, there are decreased levels of HO\textsuperscript{26-32}. Further, in a study by Cudmore M. et al. demonstrated that HO1 pathways inhibits Flt-1 release\textsuperscript{33}.

Further, haemodynamic dysregulation and its association with Renin-Angiotensin System (RAS) has also been contemplated in PE. Studies have shown that in preeclamptic women, levels of serum angiotensin I, angiotensin II and aldosterone are reduced as compared to normotensive women, and moreover, active renin levels and autoantibodies to angiotensin type 1 receptor (AT1-AAs) are increased\textsuperscript{34-36}. In a study conducted by Dechend et al. discovered that AT1-AAs causes an increase in levels of Reactive Oxygen Species (ROS), NADPH oxidase and NκB in preeclamptic women\textsuperscript{37}. Further, in studies conducted by Zhou CC et. al. demonstrated that AT1-AA induces sFlt-1 release via calcineurin pathway and also by TNF-α induction and reducing HO levels during gestation\textsuperscript{38(39)}. AT1-AA also induces production of endothelin, which is a vasoconstrictor, thus leading towards the hypertension characteristic in PE\textsuperscript{40}.

According to Roth CL. Et al., there is a decreased expression of HO-1 in vitamin D deficient obese rats\textsuperscript{41}, as well as it is proven by Oermann E. et al. that vitamin D causes upregulation of HO-1 levels\textsuperscript{42}. Further, in a study conducted by Faulkner JL et al. have demonstrated that vitamin D supplementation downregulates release and activity of AT1-AA\textsuperscript{36}.

Thus, it can be presumed that upon several etiological factors responsible for the possible prevalence of the hypertensive disorder, mere sufficient levels of vitamin D can come as a boon for its prevention. But, it should be acknowledged that for a better understanding of the effects of vitamin D levels on the prevalence of PE, more human-based trials are required to establish a direct association between the parameter and the disease. Further, the right levels of vitamin D
supplementation during gestation remains unknown, therefore, it can be suggestive of planning of more studies on investigation of a right dose of vitamin D supplement.

Acknowledgement
Authors would like to acknowledge the support rendered by the Santosh Medical College and Hospital, Ghaziabad, Uttar Pradesh.

Source of Funding: The present study was an independent study and was funded by the authors.

Conflict of Interest: None.

References
1. James M. Roberts, Phyllis A. August, George Bakris, John R. Barton, Ira M. Bernstein, Maurice Druzin, Robert R. Gaiser, Joey P. Granger, Arun Jeyabalan, Donna D. Johnson, S. Ananth Karumanchi, Marshall D. Lindheimer, Michelle Y. Owens, George R. Saade, Baha M. Sibai, Catherine Y. Spong, Eleni Tsigas, James N. Martin Jr, Gerald F. Joseph Jr, Nancy O’Reilly, Alyssa Politzer, Sarah Son, Karina Ngaiza; Hypertension in Pregnancy; American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy; American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy, developed by the Task Force on Hypertension in Pregnancy. ISBN 978-1-934984-28-4. RG575.5 618.3’6132—dc23. 201302252.
2. Reena RP, Umadevi N, Ajitha BK. Severe Obstetric Morbidity: Prevalence, Risk Factors and Outcome. Ntl J of Community Med 2015; 6(2):33-35.
3. World Health Organization. WHO recommendations for prevention and treatment of PE and eclampsia. Geneva: World Health Organization;2011
4. Snydal S. Major Changes in Diagnosis and Management of PE. J Midwifery Womens Health. 2014; 59:596–605.
5. Benachi Alexandra; Baptiste Amandine; Taieb Joëlle; Tsatsaris Vassilis; Guibourdenche Jean; SenatMarie-Victoire; Haidar Hazar; JaniJacques; Guizani Meriem; Jouannic Jean-Marie; Haguet Marie-Clotilde; Winer Norbert; Masson Damien; Courbebaisse Marie; Elie Caroline; Souberbielle Jean-Claude. Relationship between vitamin D status in pregnancy and the risk for PE: A nested case-control study. Clinical nutrition (Edinburgh, Scotland), ISSN: 1532-1983. Publication Year2019. PMID30799191. doi:10.1016/j.clnu.2019.02.015
6. Zhu-mei Fu, Zhen-zhi Ma, Guo-jie Liu, Lan-ling Wang, YongGuo; Vitamins supplementation affects the onset of PE. Journal of the Formosan Medical Association, Volume 117, Issue 1, January 2018, Pages 6-13.
7. Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. Placenta. 2009 Mar;30 Suppl A:S32-7. doi: 10.1016/j.placenta.2008.11.009. Epub 2008 Dec 13.
8. Grundmann M, Haidar M, Placzko S, Niendorf R, Darashchonak N, Hubel CA, von Versen-Hoynck F. Vitamin D improves the angiogenic properties of endothelial progenitor cells. Am J Physiol Cell Physiol. 2012;303(9):C954–C962. doi: 10.1152/ajpcell.00030.2012.
9. Merke J, Milde P, Lewicka S, Hugel U, Klaus G, Mangelsdorf DJ, Haussler MR, Rauterberg EW, Ritz E. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest. 1989; 83(6):1903–1915. doi: 10.1172/JCI114097.
10. Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1,25-
Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 2006;69(8):1377–1384. doi: 10.1038/sj.ki.5000304.

11. Brodowski L, Burlakov J, Myerski AC, von Kaisenberg CS, Grundmann M, Hubel CA, von Versen-Hoynek F. Vitamin D prevents endothelial progenitor cell dysfunction induced by sera from women with PE or conditioned media from hypoxic placenta. PLoS One. 2014;9(6):e98527. doi: 10.1371/journal.pone.0098527.

12. Woodham PC, Brittain JE, Baker AM, Long DL, Haeri S, Camargo CA, Jr, Bogess KA, Stuebe AM. Midgestation maternal serum 25-hydroxyvitamin D level and soluble fms-like tyrosine kinase 1/placental growth factor ratio as predictors of severe PE. Hypertension. 2011;58(6):1120–1125. doi: 10.1161/HYPERTENSIONAHA.111.179069.

13. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50: 1142–1147, 2007.

14. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A.: Uteroplacental ischemia results in proteinuric hypertension and elevated sFlt-1. Kidney Int71: 977–984, 2007.

15. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA.: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in PE. J Clin Invest 111: 649–658, 2003.

16. Su-ling Ma, Xiao-yu Tian, Ya-qi Wang, Hui-feng Zhang and Lei Zhang. Vitamin D Supplementation Prevents Placental Ischemia Induced Endothelial Dysfunction by Downregulating Placental Soluble FMS-Like Tyrosine Kinase-1. Published Online: 1 Dec 2017 https://doi.org/10.1089/dna.2017.3817.

17. Kulandavelu S, Whiteley KJ, Qu D, Mu J, Bainbridge SA, Adamson SL.: Endothelial nitric oxide synthase deficiency reduces uterine blood flow, spiral artery elongation, and placental oxygenation in pregnant mice. Hypertension 60: 231–238, 2012.

18. Lowe DT: Nitric oxide dysfunction in the pathophysiology of PE. Nitric Oxide 4: 441–458, 2000.

19. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med. 2010;88(5):441–450. doi: 10.1007/s00109-010-0590-9.

20. Noyola-Martinez N, Diaz L, Avila E, Halhali A, Larrea F, Barrera D. Calcitriol downregulates TNF-alpha and IL-6 expression in cultured placental cells from preeclamptic women. Cytokine. 2013;61(1):245–250. doi: 10.1016/j.cyt.2012.10.001.

21. Martinez-Miguel P, Valdivielso JM, Medrano-Andres D, Roman-Garcia P, Cano-Penalver JL, Rodriguez-Puyol M, Rodriguez-Puyol D, Lopez-Ongil S. The active form of vitamin D, calcitriol, induces a complex dual upregulation of endothelin and nitric oxide in cultured endothelial cells. Am J Physiol Endocrinol Metab. 2014 Dec 15;307(12):E1085-96. Doi: 10.1152/ajpendo.00156.2014. Epub 2014 Oct 21.

22. Bainbridge SA, Farley AE, McLaughlin BE, Graham CH, Marks GS, Nakatsu K, Brien JF, Smith GN.: Carbon monoxide decreases perfusion pressure in isolated
human placenta. Placenta 23: 563–569, 2002.
23. Zhao H, Wong RJ, Doyle TC, Nayak N, Vreman HJ, Contag CH, Stevenson DK.: Regulation of maternal and fetal hemodynamics by heme oxygenase in mice. Biol Reprod 78: 744–751, 2008
24. Lyall F, Barber A, Myatt L, Bulmer JN, Robson SC.: Heme oxygenase expression in human placenta and placental bed implies a role in regulation of trophoblast invasion and placental function. FASEB J 14: 208–219, 2000
25. McCaig D, Lyall F.: Inhibitors of heme oxygenase reduce invasion of human primary cytotrophoblast cells in vitro. Placenta 30: 536–538, 2009
26. Ahmed A, Rahman M, Zhang X, Acevedo CH, Nijjar S, Rushton I, Bussolati B, St John J.: Induction of placental heme oxygenase-1 is protective against TNFalpha-induced cytotoxicity and promotes vessel relaxation. Mol Med 6: 391–409, 2000
27. Dulak J, Dreshane J, Jozkowicz A, Agarwal A.: Heme oxygenase-1 and carbon monoxide in vascular pathobiology: Focus on angiogenesis. Circulation 117: 231–241, 2008
28. Zhao H, Wong RJ, Kalish FS, Nayak NR, Stevenson DK.: Effect of heme oxygenase-1 deficiency on placental development. Placenta 30: 861–868, 2009
29. Yachie A, Niida Y, Wada T, Igarashi N, Kaneda H, Toma T, Ohta K, Kasahara Y, Koizumi S.: Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 103: 129–135, 1999.
30. Linzke N, Schumacher A, Woidacki K, Croy BA, Zenclussen AC.: Carbon monoxide promotes proliferation of uterine natural killer cells and remodeling of spiral arteries in pregnant hypertensive heme oxygenase-1 mutant mice. Hypertension 63: 580–588, 2014
31. Barber A, Robson SC, Myatt L, Bulmer JN, Lyall F.: Heme oxygenase expression in human placenta and placental bed: Reduced expression of placenta endothelial HO-2 in PE and fetal growth restriction. FASEB J 15: 1158–1168, 2001.
32. Farina A, Sekizawa A, De Sanctis P, Purwosunu Y, Okai T, Cha DH, Kang JH, Vicenzi C, Tempesta A, Wibowo N, Valvassori L, Rizzo N.: Gene expression in chorionic villous samples at 11 weeks’ gestation from women destined to develop PE. Prenat Diagn 28: 956–961, 2008
33. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A.: Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 115: 1789–1797, 2007
34. Langer B, Grima M, Coquard C, Bader AM, Schlaeder G, Imbs JL. Plasma active renin, angiotensin I, and angiotensin II during pregnancy and in PE. Obstet Gynecol. 1998;91(2):196–202. doi: 10.1016/S0029-7844(97)00660-1.
35. Velloso EP, Vieira R, Cabral AC, Kalapothakis E, Santos RA. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I-converting enzyme deletion/deletion genotype. Brazilian J Med Biol Res. 2007;40(4):583–590. doi: 10.1590/S0100-879X2007000400018.
36. Faulkner JL, Amaral LM, Cornelius DC, Cunningham MW, Ibrahim T, Heep A, Campbell N, Usry N, Wallace K, Herse F, et al. Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in PE including hypertension. Am J Physiol Regul Integ
Comp Physiol. 2017;312(1):R125–R131. doi: 10.1152/ajpregu.00218.2016.
37. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, Luft FC.: AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation 107: 1632–1639, 2003
38. Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y.: Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 100: 88–95, 2007
39. Zhou CC, Irani RA, Zhang Y, Blackwell SC, Mi T, Wen J, Shelat H, Geng YJ, Ramin SM, Kellems RE, Xia Y.: Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in PE. Circulation 121: 436–444, 2010
40. LaMarca B, Parrish M, Ray LF, Murphy SR, Roberts L, Glover P, Wallukat G, Wenzel K, Cockrell K, Martin JN Jr., Ryan MJ, Dechend R.: Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: Role of endothelin-1. Hypertension 54: 905–909, 2009
41. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, et al. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology (2012) 55:1103–11.10.1002/hep.24737.
42. Oermann E, Bidmon HJ, Witte OW, Zilles K. Effects of 1alpha,25 dihydroxyvitamin D3 on the expression of HO-1 and GFAP in glial cells of the photothrombically lesioned cerebral cortex. J Chem Neuroanat (2004) 28:225–38.10.1016/j.jchemneu.2004.07.003.